Pemolina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pemolina" in Italian language version.

refsWebsite

Global rank Italian rank

20nih.gov

4^th place

9^th place

4oadoi.org

799^th place

22^nd place

4doi.org

2^nd place

7^th place

1fda.gov

447^th place

644^th place

doi.org

dx.doi.org

D. E. Cameron, Magnesium Pemoline and Human Performance, in Science, vol. 157, n. 3791, agosto 1967, pp. 958–959, DOI:10.1126/science.157.3791.958, PMID 5212410. URL consultato il 6 luglio 2012.
Bostic JQ, Biederman J, Spencer TJ, et al., Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial, in J Child Adolesc Psychopharmacol, vol. 10, n. 3, 2000, pp. 205–16, DOI:10.1089/10445460050167313, PMID 11052410.
W Lindau, de Girolami E, Pemoline and the prostate, in The Lancet, vol. 327, n. 8483, marzo 1986, p. 738, DOI:10.1016/S0140-6736(86)91126-8, PMID 2421119. URL consultato il 6 luglio 2012.
S. E. Polchert, R. M. Morse, Pemoline Abuse, in JAMA: The Journal of the American Medical Association, vol. 254, n. 7, 1985, pp. 946–947, DOI:10.1001/jama.1985.03360070084028, PMID 4021028. URL consultato il 6 luglio 2012.

fda.gov

Cylert and generic pemoline products, su fda.gov, U.S. Food and Drug Administration, 24 ottobre 2005. URL consultato il 25 maggio 2012.

nih.gov

ncbi.nlm.nih.gov

Lange WE, Candon BH, Chesin M, Metal chelates of oxazolidinones as central nervous system stimulants, in J Pharm Sci, vol. 51, maggio 1962, pp. 477–80, PMID 14462081.
(DE) Schmidt L, [5-Phenyl-2-imino-4-oxo-oxazolidine, a central stimulant substance], in Arzneimittelforschung, vol. 6, n. 8, agosto 1956, pp. 423–6, PMID 13373635.
Lucas CJ, Knowles JB, The trial of a new stimulant, pemoline, in the treatment of fatigue in students, in J Am Coll Health Assoc, vol. 12, dicembre 1963, pp. 187–94, PMID 14134049.
Meadley RG, A new anti-fatigue agent in general practice, in Practitioner, vol. 195, n. 169, novembre 1965, pp. 680–3, PMID 4378985.
D. E. Cameron, Magnesium Pemoline and Human Performance, in Science, vol. 157, n. 3791, agosto 1967, pp. 958–959, DOI:10.1126/science.157.3791.958, PMID 5212410. URL consultato il 6 luglio 2012.
Hoffman DJ, Sensitive GLC assay for pemoline in biological fluids using nitrogen-specific detection, in J Pharm Sci, vol. 68, n. 4, aprile 1979, pp. 445–7, PMID 438965.
Igwe OJ, Blake JW, Gas/liquid chromatographic analysis of pemoline in biological fluids using electron capture detection, in J Chromatogr Sci, vol. 19, n. 12, dicembre 1981, pp. 617–24, PMID 7328158.
Nishihara K, Kohda Y, Saitoh Y, Nakagawa F, Honda Y, Determination of pemoline in plasma, plasma water, mixed saliva, and urine by high-performance liquid chromatography, in Ther Drug Monit, vol. 6, n. 2, 1984, pp. 232–7, PMID 6740743.
Tomkins CP, Soldin SJ, MacLeod SM, Rochefort JG, Swanson JM, Analysis of pemoline in serum by high performance liquid chromatography: clinical application to optimize treatment of hyperactive children, in Ther Drug Monit, vol. 2, n. 3, 1980, pp. 255–60, PMID 7222180.
Conners CK, Taylor E, Meo G, Kurtz MA, Fournier M, Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction, in Psychopharmacologia, vol. 26, n. 4, 1972, pp. 321–36, PMID 4508756.
Knights RM, Viets CA, Effects of pemoline on hyperactive boys, in Pharmacol. Biochem. Behav., vol. 3, n. 6, 1975, pp. 1107–14, PMID 772696.
Sallee F, Stiller R, Perel J, Bates T, Oral pemoline kinetics in hyperactive children, in Clin. Pharmacol. Ther., vol. 37, n. 6, giugno 1985, pp. 606–9, PMID 4006361.
Collier CP, Soldin SJ, Swanson JM, MacLeod SM, Weinberg F, Rochefort JG, Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity, in Clin Pharmacokinet, vol. 10, n. 3, 1985, pp. 269–78, PMID 4017397.
Bostic JQ, Biederman J, Spencer TJ, et al., Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial, in J Child Adolesc Psychopharmacol, vol. 10, n. 3, 2000, pp. 205–16, DOI:10.1089/10445460050167313, PMID 11052410.
Newlands WJ, The effect of pemoline on antihistamine-induced drowsiness, in Practitioner, vol. 224, n. 1349, novembre 1980, pp. 1199–1201, PMID 6112737.
Briscoe JG, Curry SC, Gerkin RD, Ruiz RR, Pemoline-induced choreoathetosis and rhabdomyolysis, in Med Toxicol Adverse Drug Exp, vol. 3, n. 1, 1988, pp. 72–6, PMID 3367787.
Patterson JF, Hepatitis associated with pemoline, in South. Med. J., vol. 77, n. 7, luglio 1984, p. 938, PMID 6740368.
Dickinson LC, Lee J, Ringdahl IC, Schedewie HK, Kilgore BS, Elders MJ, Impaired growth in hyperkinetic children receiving pemoline, in J. Pediatr., vol. 94, n. 4, aprile 1979, pp. 538–41, PMID 430289.
W Lindau, de Girolami E, Pemoline and the prostate, in The Lancet, vol. 327, n. 8483, marzo 1986, p. 738, DOI:10.1016/S0140-6736(86)91126-8, PMID 2421119. URL consultato il 6 luglio 2012.
S. E. Polchert, R. M. Morse, Pemoline Abuse, in JAMA: The Journal of the American Medical Association, vol. 254, n. 7, 1985, pp. 946–947, DOI:10.1001/jama.1985.03360070084028, PMID 4021028. URL consultato il 6 luglio 2012.

oadoi.org

D. E. Cameron, Magnesium Pemoline and Human Performance, in Science, vol. 157, n. 3791, agosto 1967, pp. 958–959, DOI:10.1126/science.157.3791.958, PMID 5212410. URL consultato il 6 luglio 2012.
Bostic JQ, Biederman J, Spencer TJ, et al., Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial, in J Child Adolesc Psychopharmacol, vol. 10, n. 3, 2000, pp. 205–16, DOI:10.1089/10445460050167313, PMID 11052410.
W Lindau, de Girolami E, Pemoline and the prostate, in The Lancet, vol. 327, n. 8483, marzo 1986, p. 738, DOI:10.1016/S0140-6736(86)91126-8, PMID 2421119. URL consultato il 6 luglio 2012.
S. E. Polchert, R. M. Morse, Pemoline Abuse, in JAMA: The Journal of the American Medical Association, vol. 254, n. 7, 1985, pp. 946–947, DOI:10.1001/jama.1985.03360070084028, PMID 4021028. URL consultato il 6 luglio 2012.